21 year follow-up in Dutch arm of European #prostatecancer screening trial shows greater reduction in cancer mortality (27%) and de novo metastatic cancer, and lower number needed to invite (121) or diagnose (7) 1 metastatic cancer European Urology study #pcsm europeanurology.com/article/S0302-…

This three-pager is a must-read by every oncologist. Chris Booth is one of my heroes #timetoxicity “Thus, intensive treatments associated with more time toxicity are not incorrect choices themselves, and decisions for patients should be individualized. The most important first

Happy to share 15 y results of RARP in men w localized PCa diagnosed in the current PSA screen era. Few takeaways: - longest FU, median >14 y - detailed 5 onc/survival outcomes - risk stratified w 608 and 312 IR and HR patients (lacking in ProtecT) nature.com/articles/s4139…

As a cardiologist, every day I see 2-3 patients who need clearance for surgery 🔪 ALL of them are on blood thinners🩸 Every surgeon wants to stop these medicines💊 The patients ask: Is it safe? Should I stop? Let's see how to deal with blood thinners before surgery 🧵👇

Prostate cancer does not receive the policy attention it deserves. Please share this short testimonial for the PRAISE-U project and encourage others to participate in this important initiative. Let’s add Prostate Cancer to the table on men’s health policy. audiovisual.ec.europa.eu/en/video/I-244…

Quality Control Indicators for Transurethral Resection of Bladder Tumor: Results from an Embedded Belgian Multicenter Prospective Registry buff.ly/3OL6tOZ Murat Akand Yannic Raskin Cedric Jorissen Siska Van Bruwaene steven joniau Frank Van der Aa #bladder #UroSoMe #Medtwitter

The BAU2023 congress is coming up! 1 & 2 December ⁦Hilton Hotels⁩ Antwerp. Interested in submitting a poster? Submission deadline is October 31. Please find the template on our website. #BAU2023 ⁦Société Belge d'Urologie⁩ ⁦European Association of Urology (EAU)⁩ ⁦ESRU Belgium⁩ bau.be/programme/

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

423 start Move against Prostate Cancer persconferentie op OHLeuven steven joniau BVU Scientific Summits

Vandaag de start van de “423” campagne OH Leuven met Club Brugge KV : van 4 doden per dag aan prostaatkanker in België naar 3 door awareness en early detection! #Move against prostate cancer ! Société Belge d'Urologie European Association of Urology (EAU) ESRU Belgium steven joniau Thomas Adams Marc Claessens Pieter Uvin Hein Van Poppel

Schitterend interview met onze BVU ondervoorzitter Prof Steven Joniau steven joniau ! #prostaat #prostaatkanker nieuwsblad.be/cnt/dmf2023112…

Great talk today by Tom Marcelissen about the history of surgery. Revolutionary ideas are often hiding in plain sight!

1/4 Transperineal Versus Transrectal Magnetic Resonance Imaging–targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial - ScienceDirect. sciencedirect.com/science/articl…

🚨Keep screening Prostate cancer!🚨 Non-screening policies lead to more agressive and invasive cancers with worse operative outcomes. This is our experience with 11.300 patients operated by a single surgeon in our center. celebrationgri vincenzo ficarra Bernardo Rocco

🔓Salvage vesiculectomy for local prostate cancer recurrence: surgical technique and early post‑operative outcomes #PCaTreatment DOI: doi.org/10.1007/s00345… steven joniau Thomas VandenBroeck Dries Develtere Yannic Raskin Kevin Wymer Christopher Eden Kato Rans Charlien Berghen Gert De Meerleer

Proud to present the final results of the MEDCARE phase II study published in European Urology Oncology! Progression-directed Therapy in Oligoprogressive Castration-resistant Prostate Cancer! ⚡️ Gert De Meerleer steven joniau Karolien Goffin Charlien Berghen Haustermans authors.elsevier.com/c/1i~Pq9Cfv--d…

The EB-StaR study was published at European Urology today! ✅ It is a randomised study comparing en bloc resection of bladder tumour (ERBT) and conventional transurethral resection of bladder tumour (TURBT) in patients with bladder tumour(s) <= 3 cm in size. 🏥 #UroSoMe (1/n)

IMPACT: Long-term Prostate Cancer-specific Mortality After Prostatectomy, Brachytherapy, External Beam Radiation Therapy, Hormonal Therapy, or Monitoring for Localized Prostate Cancer by Annika Herlemann et al Full article: europeanurology.com/article/S0302-… Annika Herlemann #UroSoMe #PCa

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…

Final results of National Cancer Institute RCT of Transperineal vs Transrectal Prostate Biopsy jamanetwork.com/journals/jamao…